76 measured with a reduced size e correlate the rate of at least 10% was achieved significant improvements in symptoms QoL.87 and my, 88 ruxoliti After a median follow-up of 52 weeks Nib and 51 weeks in the placebo group, there were 13 and 24 Todesf Ll get engaged, each with a hazard ratio of 0.50, meaning that Ruxolitinib k Can the lives of patients with advanced MF.85 COMFORT II is Ngern showed a double-blind phase III study of 219 patients with MF, in nine europ European L performed change. Patients were randomized Ruxolitinib Calcium Channel review or the best available therapy. Ruxolitinib dose was 15 mg / bid, or 20 mg / bid,, and has adjusted the range of 5 mg / 25 mg bid / offer. BAT may be oral, parenteral, or no treatment. Erm Igungen in spleen volume of $ 35% at weeks 48 and 24 were the primary Ren and secondary endpoints Re keys or. The prime Re endpoint was reached by 28.5% and 0% Ruxolitinib beneficiaries BAT, and the secondary Re endpoint of 31. 9% and 0% response rate was also 0.75 h Ago as Ruxolitinib for BAT in subgroups on the Based JAK2V617F mutation status, risk group, MF-type, hydroxyurea treatment, the size s or the volume of the base rate, age and sex.89 symptoms measured by the EORTC QLQ C30 my significant improvements in Ruxolitinib group from week 8 to continuous improvement through week 48 were compared Cyt387 BAT.90 also my grades in the sub-functional evaluation system Lymphoma Cancer 91 therapy improved treatment Ruxolitinib. No significant difference between the subgroups based risk beneficiaries found Ruxolitinib. A post hoc comparison of the COMFORT I and COMFORT II placebo BAT signif icant difference showed no symptom And my Lebensqualit t. Increased in the placebo group, the median of the spleen in Week 24 Ht and 8. 5% in the BAT group 5.1% 0.92 Conclusion In clinical trials, serious Ruxolitinib ged Fights manifestations of MF, n Namely splenomegaly and the main symptoms my illness. Patients experienced reductions in spleen volume drops per circulating inflammatory cytokines, weight gain, and significant improvements in the symptoms And my Lebensqualit t. Based on efficacy and reps Opportunity in clinical trials Ruxolitinib the first drug approved by the U.S. Food and Drug Administration approved in mid-November 2011, for the treatment of MF, and now has a place among the most important opportunities Behandlungsm Available. The reported data suggest that these effects are independent Ngig of patient characteristics, including normal age, subtype MF, risk group, JAK2V617F mutation status, L Length of the base interest rate available, and the H Hemoglobin base. Although the data from the COMFORT is I Phase III study that Ruxolitinib the lives of patients with advanced MF Ruxolitinib agrees on has no curative potential of the disease. On the other hand, the advantages seem Ruxolitinib significant and clinically significant other therapeutic modality Th currently in allogeneic h Provide hematopoietic stem cells used Ethical is not an option. Moreover, it may be useful to patients unsuitable for allogeneic h Pretreat hematopoietic stem cell Ethical, perhaps to help them be suitable for clinical transplantation. However, it should prove in clinical trials.